Short CommunicationEffect of Amiodarone on the Serum Concentration/Dose Ratio of Metoprolol in Patients with Cardiac Arrhythmia
References (49)
Drug interactions with amiodarone
Am. Heart J.
(1983)- et al.
Steady-state interaction between amiodarone and phenytoin in normal subjects
Am. J. Cardiol.
(1990) - et al.
Flecainide and amiodarone interaction
J. Am. Coll. Cardiol.
(1986) - et al.
Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol
Am. Heart J.
(1988) - et al.
Effect of amiodarone on the plasma levels of metoprolol
Am. J. Caldiol.
(2004) - et al.
Sensitive determination of bisoprolol enantiomers in plasma and urine by high-performance liquid chromatography using fluorescence detection, and application to preliminary study in human
J. Chromatogr.
(1993) - et al.
Interaction of metoprolol and fluoxetine
Lancet
(1993) Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial
J. Clin. Pharmacol.
(1991)A classification of antiar-rhythmic actions reassessed after a decade of new drugs
J. Clin. Pharmacol.
(1984)- et al.
Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias
Drugs
(1992)
Pharmacokinetic drug interactions with amiodarone
Clin. Pharmacokinet.
Clinical pharmacokinetics of amiodarone
Clin. Pharmacokinet.
Amiodarone: the expanding antiar-rhythmic role and how to follow a patient on chronic therapy
Clin. Cardiol.
use of antiarrhythmics and implantable cardioverter-defibrillators in congestive heart failure
Am. J. Cardiol.
Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions
Br. J. Clin. Pharmacol.
A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor
Drug Metab. Dispos.
Pharmacokinetic drug interactions with amiodarone
Clin. Pharmacokinet.
The mechanism of the interaction between amiodarone and warfarin in humans
Clin. Pharmacol. Ther.
Amiodarone reduces plasma warfarin clearance in man
Br. J. Clin. Pharmacol.
Mechanism of warfarin potentiation by amiodarone: dose-and concentration-dependent inhibition of warfarin elimination
Eur. J. Clin. Pharmacol.
Effect of phenytoin on the clinical pharmacokinetics of amiodarone
J. Clin. Pharmacol.
Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers
Clin. Pharmacol. Ther.
Potent inhibition of cytochrome P450IID6 (debrisoquine 4-hydroxylase) by flecainide in vitro and in vivo
J. Cardiovasc. Pharmacol.
Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone
Clin. Pharmacol. Ther.
Cited by (26)
UPLC-MS/MS for simultaneous quantification of vortioxetine and its metabolite Lu AA34443 in rat plasma and its application to drug interactions
2020, Arabian Journal of ChemistryCitation Excerpt :Dronedarone is a novel antiarrhythmic drug, and has been shown to inhibit CYP2D6 (Patel, Yan, & Kowey, 2009). Amiodarone, the most commonly used antiarrhythmic agent, is also found to be an inhibitor of CYP2D6 (Fukumoto et al., 2006; Jaruratanasirikul & Hortiwakul, 1994; Ohyama et al., 2000). In clinic, patients with MDD may develop arrhythmias.
Pharmacologic interactions
2018, Cardiac Intensive CareLotus leaf alkaloid fraction can strongly inhibit CYP2D6 isoenzyme activity
2016, Journal of EthnopharmacologyCitation Excerpt :The enzyme CYP2D6 catalyzes approximately 30% of market drugs, although it is a relatively minor fraction of all the hepatic P450 enzymes. Many conventional Western medicines, including antidepressive drugs (fluoxetine and amitriptyline), β-receptor blocking agents (metoprolol and propranolol) (Fukumoto et al., 2006), and antipsychotic drugs (chlorpromazine, perphenazine, and tamoxifen) (Li et al., 2011), are the substrates of CYP2D6. Inhibition of this isoenzyme may result in adverse drug interactions in the clinic because the enzyme inhibition may lead to increased plasma levels of another drug administered concomitantly, and drug-induced toxicity.
Natural products-friends or foes?
2015, Toxicology LettersCitation Excerpt :The lotus leaf alcoholic extract, rich in aporphine alkaloids, was found to be a strong inhibitor of the CYP2D6 isoenzyme. This isozyme catalyzes approximately 30% of the clinically encountered drugs (antidepressive drugs – fluoxetine and amitriptyline, β-blocking agents – metoprolol and propranolol, antipsychotic drugs – chlorpromazine, perphenazine, and even tamoxifen) and its inhibition may result in potential adverse drug interactions leading to increased plasma levels of another drug administered concomitantly and resulting in drug-induced toxicity (Ye et al., 2014; Fukumoto et al., 2006; Li et al., 2011). While the interactions of natural products and herbal constituents upon the metabolic capacity of drug metabolizing enzymes are apparent, the impact of genetic polymorphisms of the latter is a matter of increasing alert for patients and clinicians.
Identification and characterization of potent CYP2D6 inhibitors in lotus leaves
2014, Journal of EthnopharmacologyCitation Excerpt :Although CYP2D6 is a relatively minor fraction of the total hepatic CYP content, it catalyzes approximately 30% of the drugs in the market, and inhibition of this isoenzyme may result in potential adverse drug interactions in the clinic because the inhibition of this drug-metabolizing enzyme may lead to increased plasma levels of another drug administered concomitantly and result in drug-induced toxicity. The result suggests that the use of lotus leaves and their preparations containing high contents of aporphine alkaloids may cause interactions with the substrates of CYP2D6, including antidepressive drugs, such as fluoxetine and amitriptyline, β-receptor blocking agents, such as metoprolol and propranolol (Fukumoto et al., 2006), and antipsychotic drugs, such chlorpromazine, perphenazine, and tamoxifen (Li et al., 2011). It is also important to note that other unidentified and low-content alkaloids may contribute the inhibitory effect on CYP2D6 enzyme, since other aporphine alkaloids, such as liriodenine, dehydroroemerine, and dehydronuciferine have also been found in lotus leaves (Wang et al., 2009).
Pharmacologic interactions in the cicu
2010, Cardiac Intensive Care: Expert Consult